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Abstract
Copyright © 2018 L. R. Galieva et al. Spinal cord injury (SCI) unavoidably results in death of not
only neurons but also glial cells. In particular, the death of oligodendrocytes leads to impaired
nerve impulse conduction in intact axons. However, after SCI,  the Schwann cells (SCs) are
capable of migrating towards an area of injury and participating in the formation of functional
myelin.  In  addition  to  SCI,  cellbased therapy can influence the  migration  of  SCs  and the
expression of their molecular determinants. In a number of cases, it can be explained by the
ability of implanted cells to secrete neurotrophic factors (NTFs). Genetically modified stem and
progenitor cells overexpressing NTFs have recently attracted special attention of researchers
and are most promising for the purposes of regenerative medicine. Therefore, we have studied
the  effect  of  genetically  modified  human  umbilical  cord  blood  mononuclear  cells  on  the
expression of SC molecular determinants in SCI.
http://dx.doi.org/10.1155/2018/4695275
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